With more than $15 billion raised in VC funding for platform biotechs in 2022, investors have been attracted to areas such as the integration of large omics data sets, investigation of regenerative medicines, and unlocking of large-scale genomic edits.
With more than $15 billion raised in VC funding for platform biotechs in 2022, investors have been attracted to areas such as the integration of large omics data sets, investigation of regenerative medicines, and unlocking of large-scale genomic edits. These areas of development indicate where innovative biotech may be heading.